We also achieved the hidden goal of Bill Gates doing exactly what David Manheim suggested and building facilities for the 7 top vaccine candidates, which is the best result for any of these questions so far if you don’t look too closely at causality.
This leaves two questions:
A) How do we speed up vaccine approval, given that the supply is taken care of?
B) What do we want to do with the surplus factories?
Let’s start with A. If we want faster vaccine approval, we can have it, if we do our clinical trials faster. If we reduce our safety expectations for our clinical trials we can start human trials sooner. CureVac could likely start their trial much sooner if European regulators wouldn’t advice them to wait. Furthermore, we could decrease the trial duration by infecting patients in the trial with the virus.
As far as B goes, we might want to do more vaccination in general. Giving out more BCG vaccines might be a good idea for general health benefits. We should check whether other vaccines have similar positive effects.
This leaves two questions:
A) How do we speed up vaccine approval, given that the supply is taken care of?
B) What do we want to do with the surplus factories?
Let’s start with A. If we want faster vaccine approval, we can have it, if we do our clinical trials faster. If we reduce our safety expectations for our clinical trials we can start human trials sooner. CureVac could likely start their trial much sooner if European regulators wouldn’t advice them to wait. Furthermore, we could decrease the trial duration by infecting patients in the trial with the virus.
As far as B goes, we might want to do more vaccination in general. Giving out more BCG vaccines might be a good idea for general health benefits. We should check whether other vaccines have similar positive effects.